ConductScience.org, home

Paper6392147

A phase I trial of cis-diammine-1,1-cyclobutane dicarboxylate platinum II (Carboplatin, CBDCA, JM-8) with a single dose every five week-schedule.

Joss RA and 5 others. Invest New Drugs, 1984. Cited by 42 papers, by iCite.

Cite this record

ConductScience Library. A phase I trial of cis-diammine-1,1-cyclobutane dicarboxylate platinum II (Carboplatin, CBDCA, JM-8) with a single dose every five week-schedule. Papers, record 6392147. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/6392147

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
A phase I trial of cis-diammine-1,1-cyclobutane dicarboxylate platinum II (Carboplatin, CBDCA, JM-8) with a single dose every five week-schedule.
PubMed
Journal
Invest New Drugs
PubMed
Year
1984
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
42
iCite
Relative citation ratio, by iCite
1.93
iCite
Revised in PubMed
2019-10-23
PubMed

Authors6

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Joss RAR A
2Kaplan SS
3Goldhirsch AA
4Sessa CC
5Brunner KWK W
6Cavalli FF

Source PubMed

Download CSV of authors

Topics16

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Antineoplastic AgentsMajor topic
Organoplatinum CompoundsMajor topic
Adult
Aged
Blood
Carboplatin
Creatinine
Digestive System
Drug Administration Schedule
Drug Evaluation
Female
Humans
Kidney
Male
Middle Aged
Neoplasms

Source PubMed

Download CSV of topics

References11

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
16342774New platinum complexes in clinical trials.Cancer Treat Rev1983https://conductscience.org/library/papers/6342774PubMed
2227599Phase II trial of cis-dichlorodiammineplatinum(II) in advanced malignant lymphoma and small cell lung cancer: preliminary results.Cancer Treat Rep1979https://conductscience.org/library/papers/227599PubMed
3387223Toxic effects of cis-dichlorodiammineplatinum(II) in man.Cancer Treat Rep1979https://conductscience.org/library/papers/387223PubMed
47198010Antitumor activity and toxicity of cisplatin analogs.Cancer Treat Rep1982https://conductscience.org/library/papers/7198010PubMed
56131277JMS, successor to cisplatin in advanced ovarian carcinoma?Lancet1983https://conductscience.org/library/papers/6131277PubMed
66761010Early clinical studies with cis-diammine-1,1-cyclobutane dicarboxylate platinum II.Cancer Chemother Pharmacol1982https://conductscience.org/library/papers/6761010PubMed
76258791High-dose cisplatin with fluid and mannitol-induced diuresis in advanced lung cancer: a phase II clinical trial of the EORTC Lung Cancer Working Party (Belgium).Cancer Treat Rep1980https://conductscience.org/library/papers/6258791PubMed
86366128Phase I study of carboplatin given on a five-day intravenous schedule.J Clin Oncol1983https://conductscience.org/library/papers/6366128PubMed
9378370Cisplatin (cis-diamminedichloroplatinum II).Cancer Treat Rev1979https://conductscience.org/library/papers/378370PubMed
10498152Nephrotoxicity of cis-dichlorodiammineplatinum(II).Cancer Treat Rep1979https://conductscience.org/library/papers/498152PubMed
116347373A phase I and pharmacokinetic study of diamminecyclobutane-dicarboxylatoplatinum (NSC 241240).Cancer Res1983https://conductscience.org/library/papers/6347373PubMed

Download CSV of references

Cited by6

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 42 citations.

PMIDTitleJournalYearIn PapersSource
28060758Exosomes as mediators of platinum resistance in ovarian cancer.Oncotarget2017https://conductscience.org/library/papers/28060758PubMed
8880388New drug development for pediatric oncology.Invest New Drugs1996https://conductscience.org/library/papers/8880388PubMed
3689665Pharmacokinetics of ethylenediaminemalonatoplatinum(II) (JM-40) during phase I trial.Br J Cancer1987https://conductscience.org/library/papers/3689665PubMed
2559261Carboplatin in association with etoposide and either adriamycin or epirubicin for untreated small cell lung cancer: a dose escalation study of carboplatin. UCL Clinical Oncology Group.Med Oncol Tumor Pharmacother1989https://conductscience.org/library/papers/2559261PubMed
2191847Antineoplastic drugs in 1990. A review (Part II).Drugs1990https://conductscience.org/library/papers/2191847PubMed
2178792A strategy for the development of two clinically active cisplatin analogs: CBDCA and CHIP.Cancer Chemother Pharmacol1990https://conductscience.org/library/papers/2178792PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/6392147

GET https://conductscience.org/api/papers/v1/6392147/authors